There's a unique therapy option for Hoosiers with disabilities or who are battling a mental health challenge.
The FDA approved the drug for people who are considered obese, with a body mass index of 30 or higher, or those who are overweight with a related health condition.INDIANAPOLIS — A new version of the popular diabetes treatment Mounjaro can be sold as a weight-loss drug, U.S. regulators announced Wednesday.Zepbound is the latest diabetes drug approved for weight loss, joining Novo Nordisk's Wegovy, a high-dose version of its diabetes treatment Ozempic.
Touted by celebrities and on social media, semaglutide and tirzepatide drugs have already been in such demand that their manufacturers have struggled to keep up. Both have been listed on the FDA’s drug shortage site for months. All strengths of tirzepatide are currently listed as available, but a company spokesperson said that could vary by location and demand.
While experts lauded approval of Zepbound, they worried that it wouldn't necessarily mean greater access to the drug, which has been prescribed “off-label” to help people pare pounds.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
FDA approves new obesity drug from Eli Lilly named ZepboundThe decision by the Food and Drug Administration is expected to add to the demand for a new class of drugs transforming how patients battle obesity.
Read more »
FDA approves Eli Lilly’s Zepbound, a weight loss drug similar to Ozempic and WegovyBerkeley Lovelace Jr. is a health and medical reporter for NBC News. He covers the Food and Drug Administration, with a special focus on Covid vaccines, prescription drug pricing and health care. He previously covered the biotech and pharmaceutical industry with CNBC.
Read more »
Eli Lilly's Obesity Drug Gets FDA ApprovalThe drug will be marketed as an obesity treatment under the name Zepbound.
Read more »
Eli Lilly gets FDA approval for new obesity drugZepbound helped patients lose up to 48 pounds on average in clinical trials
Read more »
FDA approves a new weight loss drug, Zepbound from Eli LillyThe medication, tirzepatide, was previously approved as Mounjaro for diabetes and will now be marketed as Zepbound for weight loss.
Read more »
Eli Lilly’s Mounjaro Approved for Weight Loss in the U.S.The drug, which will be sold as Zepbound as an anti-obesity treatment, had previously been cleared by the FDA for the treatment of Type 2 diabetes
Read more »